GlaxoSmithKline begins phase III study of subcutaneous Benlysta

GlaxoSmithKline has commenced a phase III clinical trial of a new subcutaneous formulation of its systemic lupus erythematosus (SLE) treatment Benlysta.

In association with partner Human Genome Sciences, the company has initiated dosing for patients enrolled in the Bliss-SC study, which aims to assess the safety, efficacy and tolerability of the new treatment option.

More than 800 autoantibody-positive patients with active SLE will be involved in the trial, which combines Benlysta with the current standard of care and will compare its performance to a placebo-based regimen.

It is being conducted at more than 200 sites globally, with results expected in the second half of 2014.

Thomas Watkins, president and chief executive officer of Human Genome Sciences, said: "Initiation of this new trial investigating a subcutaneous formulation of Benlysta represents an important step in our ongoing clinical development programme."

This comes after GlaxoSmithKline announced a new partnership with Help for Heroes earlier this month, which is aimed at supporting the creation of a new UK rehabilitation centre for wounded ex-servicemen and women.